Evidence map›Paper›PMID 32613204›Full record

ArticleNature cancer2020

Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.

Steven M Corsello, Rohith T Nagari, Ryan D Spangler, Jordan Rossen, Mustafa Kocak, Jordan G Bryan, Ranad Humeidi, David Peck, Xiaoyun Wu, Andrew A Tang and 28 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 568 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
568citing papers in PubMed, 1 pooled it
39.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

568 citing papers in PubMed, 1 synthesis or guideline pooled it, 856 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

508 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors at 1 institution in 2 countries.

Steven M CorselloBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9929-3709
Rohith T NagariBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Ryan D SpanglerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jordan RossenBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Mustafa KocakBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jordan G BryanBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4984-0516
Ranad HumeidiBroad Institute of MIT and Harvard, Cambridge, MA, USA.
David PeckBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Xiaoyun WuBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Andrew A TangBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Vickie M WangBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Samantha A BenderBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Evan LemireBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Rajiv NarayanBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Philip MontgomeryBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Uri Ben-DavidBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-7098-2378
Colin W GarvieBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Yejia ChenBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Matthew G ReesBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-2987-7581
Nicholas J LyonsBroad Institute of MIT and Harvard, Cambridge, MA, USA.
James M McFarlandBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Bang T WongBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Li WangBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Nancy DumontBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Patrick J O'HearnBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Eric StefanBroad Institute of MIT and Harvard, Cambridge, MA, USA.
John G DoenchBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3707-9889
Caitlin N HarringtonBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Heidi GreulichBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Matthew MeyersonBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-9133-8108
Francisca VazquezBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Aravind SubramanianBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Jennifer A RothBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Joshua A BittkerBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4166-0828
Jesse S BoehmBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Christopher C MaderBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Aviad TsherniakBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-3797-1877
Todd R GolubBroad Institute of MIT and Harvard, Cambridge, MA, USA. golub@broadinstitute.org.ORCID http://orcid.org/0000-0003-0113-2403
Broad Institute · US

Funding

Discovering existing medicines that abrogate cellular responses to SARS CoV-2 infectionU54HL127366 · NHLBI · BROAD INSTITUTE, INC. · PI GOLUB, TODD R. · 2014 to 2020
$14.3M
There and Back Again: Epigenetic Reinforcement of Cellular Signaling States - OverallU54HG008097 · NHGRI · BROAD INSTITUTE, INC. · PI JAFFE, JACOB DAVID · 2014 to 2019
$9.3M
Institutional Career Development CoreKL2TR002542 · NCATS · HARVARD MEDICAL SCHOOL · PI BREDELLA, MIRIAM ANTOINETTE, RUTKOVE, SEWARD B. · 2018 to 2022
$8.7M
LINCS Data Coordination and Integration CenterU01HG008699 · NHGRI · BROAD INSTITUTE, INC. · PI GOLUB, TODD R., SUBRAMANIAN, ARAVIND · 2015 to 2019
$3.2M
Targeting casein kinase 1-alpha for cancer therapyK08CA230220 · NCI · STANFORD UNIVERSITY · PI CORSELLO, STEVEN MUNTEAN · 2018 to 2022
$1.0M
NCATS NIH HHS KL2 TR002542NCI NIH HHS K08 CA230220NHGRI NIH HHS U01 HG008699NHGRI NIH HHS U54 HG008097NHLBI NIH HHS U54 HL127366
6 · The paper itself

Abstract

Anti-cancer uses of non-oncology drugs have occasionally been found, but such discoveries have been serendipitous. We sought to create a public resource containing the growth inhibitory activity of 4,518 drugs tested across 578 human cancer cell lines. We used PRISM, a molecular barcoding method, to screen drugs against cell lines in pools. An unexpectedly large number of non-oncology drugs selectively inhibited subsets of cancer cell lines in a manner predictable from the cell lines' molecular features. Our findings include compounds that killed by inducing PDE3A-SLFN12 complex formation; vanadium-containing compounds whose killing depended on the sulfate transporter SLC26A2; the alcohol dependence drug disulfiram, which killed cells with low expression of metallothioneins; and the anti-inflammatory drug tepoxalin, which killed via the multi-drug resistance protein ABCB1. The PRISM drug repurposing resource (https://depmap.org/repurposing) is a starting point to develop new oncology therapeutics, and more rarely, for potential direct clinical translation.

Indexed as

NeoplasmsCell LineDisulfiramDrug RepositioningHumansDisulfiram

Identifiers

PMID32613204
PMCPMC7328899
OpenAlexW3003119869

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.